Goldman Sachs Boosts Biogen Stock Target Amid New Alzheimer's Strategy

Goldman Sachs has raised its price target for Biogen, suggesting increased confidence in the company's recent strategy concerning Alzheimer's treatment.

This revision reflects analysts' optimism about Biogen's potential to make significant advancements in addressing Alzheimer's disease.

The update comes as Biogen explores new avenues in its treatment approach, which may enhance its market position.